SCHEMBL2981272

SCHEMBL2981272

NCCCC[C@H](O)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.60
GPR84 Q9NQS5 3/20 0.58
RNPEP Q9H4A4 1/20 0.58
FFAR1 O14842 1/20 0.58
CPB2 Q96IY4 4/20 0.52
TET2 Q6N021 3/20 0.48
KDM4A O75164 2/20 0.48
KDM4C Q9H3R0 2/20 0.48
KDM2A Q9Y2K7 2/20 0.48
TET3 O43151 1/20 0.48
FOLH1 Q04609 1/20 0.44
CYP2D6 P10635 1/20 0.44
NFKB1 P19838 1/20 0.44
BLM P54132 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
PLG P00747 1/20 0.42
LMNA P02545 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL168957 1.00 GSR (0.60) GSRGPR84RNPEPFFAR1CPB2
SCHEMBL17262908 1.00 GSR (0.60) GSRGPR84RNPEPFFAR1CPB2
SCHEMBL7027171 0.98 GPR84 (0.61) GSRGPR84RNPEPFFAR1CPB2
SCHEMBL7874857 0.98 GPR84 (0.61) GSRGPR84RNPEPFFAR1CPB2
SCHEMBL7925235 0.98 GPR84 (0.61) GSRGPR84RNPEPFFAR1CPB2
SCHEMBL4820853 0.92
SCHEMBL3347601 0.92
SCHEMBL4819961 0.92
SCHEMBL28089828 0.88 GPR84 (0.81) GSRGPR84FFAR1MEN1ALDH1A1
SCHEMBL11651698 0.87 GPR84 (0.71) GSRGPR84FFAR1TET2KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107299072-A Engineering bacterium and application thereof 江南大学 2017-10-27 CN claimed
EP-1117720-A4 POLYESTER ANALOGUE OF POLY-L-LYSINE AS A SOLUBLE, BIODEGRADABLE GENE DELIVERY CARRIER EXPRESSION GENETICS INC (US) 2001-11-14 EP claimed
EP-1117720-A1 POLYESTER ANALOGUE OF POLY-L-LYSINE AS A SOLUBLE, BIODEGRADABLE GENE DELIVERY CARRIER Expression Genetics, Inc. (US) 2001-07-25 EP claimed
US-6217912-B1 POLY((4-AMINOBUTYL-)GLYCOLIC ACID EXPRESSION GENETICS, INC. 2001-04-17 US claimed
WO-2000002950-A9 POLYESTER ANALOGUE OF POLY-L-LYSINE AS A SOLUBLE, BIODEGRADABLE GENE DELIVERY CARRIER EXPRESSION GENETICS INC (US) 2000-07-20 WO claimed
WO-2000002950-A1 POLYESTER ANALOGUE OF POLY-L-LYSINE AS A SOLUBLE, BIODEGRADABLE GENE DELIVERY CARRIER EXPRESSION GENETICS, INC. (US) 2000-01-20 WO claimed
US-20250206782-A1 BIOLOGICAL POLYMERS RES & INNOVATION UK (GB) 2025-06-26 US disclosed
US-11911488-B2 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy THE JOHNS HOPKINS UNIVERSTY (US) 2024-02-27 US disclosed
CN-117551696-A Composition for transfecting nucleic acid molecules into cells comprising triazole compounds grafted onto cationic polymers and uses thereof 宝利普拉斯生物转染公司 2024-02-13 CN disclosed
CN-114901316-B Composition for transfecting nucleic acid molecules into cells comprising triazole compounds grafted onto cationic polymers and uses thereof 宝利普拉斯生物转染公司 2024-02-13 CN disclosed
CN-117440824-A RNA vaccine against SARS-CoV-2 variants 库瑞瓦格欧洲公司 2024-01-23 CN disclosed
CN-117337330-A TMEM173 saRNA compositions and methods of use 米纳治疗有限公司 2024-01-02 CN disclosed
WO-2023183906-A2 COMPOSITIONS AND METHODS FOR ENHANCING INTRA-MITOCHONDRIAL PROTEIN TRANSLATION AND OXIDATIVE PHOSPHORYLATION THE BROAD INSTITUTE, INC. (US) 2023-09-28 WO disclosed
US-4703043-A Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive E. R. SQUIBB & SONS, INC. (US) 1987-10-27 US disclosed
EP-0239109-A2 Phosphonate angiotensin converting enzyme inhibitors E.R. Squibb & Sons, Inc. (US) 1987-09-30 EP disclosed
US-4686298-A Intermediates for alpha-acyloxy phosphonate angiotensin converting enzyme inhibitors E. R. SQUIBB & SONS, INC. (US) 1987-08-11 US disclosed
CN-87100055-A Orally active phosphonyl hydroxyacyl proline and preparation method thereof 1987-08-05 CN disclosed
EP-0229520-A1 Orally active phosphonyl hydroxyacyl prolines and processes for preparing phosphonyl hydroxyacyl prolines E.R. Squibb & Sons, Inc. (US) 1987-07-22 EP disclosed
US-4670422-A HYPOTENSIVE AGENT, ANALGESICS E. R. SQUIBB & SONS, INC. (US) 1987-06-02 US disclosed
US-4616005-A Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives E. R. SQUIBB & SONS, INC. (US) 1986-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11911488-B2 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy FOLH1, PSMA3, PSMA7 GSR 1828/4885GPR84 452/4885RNPEP 226/4885
US-20250206782-A1 BIOLOGICAL POLYMERS NSUN3, AARS1, TARBP1 GSR 3182/4885GPR84 4040/4885RNPEP 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.